Plaque, Amyloid: Clinical Trials

27 trials for Plaque, Amyloid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 not yet recruiting, 3 recruiting, 2 unknown. 27 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 127Completed 16, Not yet recruiting 3, Recruiting 3, Unknown 2, Withdrawn 2, Terminated 1
Phase 26Completed 3, Recruiting 1, Terminated 1, Unknown 1

Follow Plaque, Amyloid: new trials by email Literature Review of Plaque, Amyloid trials Research Report on Plaque, Amyloid

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
LY4560736, Placebo, Florbetapir F18 - Healthy Volunteers, Alzheimer Disease
Phase 1Not yet recruitingEli Lilly and Company1112026-10-012026-10-08
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
8M2D, Placebo - Alzheimer's Disease (AD)
Phase 1Not yet recruitingCenna Biosciences Inc.542026-09-152026-05-05
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
LY4405094, Placebo, Florbetapir F18 - Alzheimer Disease, Amyloid
Phase 1RecruitingEli Lilly and Company1792026-09-092026-11-05
Prospective Single-Arm Safety Study of Cervical LVA in AD Patients
Supermicrosurgical Lymphaticovenular Anastomosis (LVA) - Alzheimer's Disease (AD)
Phase 1Not yet recruitingChang Gung Memorial Hospital352026-03-012026-03-09
A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants
GSM-779690T, Placebo - Healthy Adult Participants
Phase 1WithdrawnActa Pharmaceuticals2025-11-092026-01-07
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
LY4405094, Placebo, Florbetapir F18 - Healthy Volunteers, Alzheimer Disease
Phase 1RecruitingEli Lilly and Company682025-10-142026-10-22
Propolis Lozenges Extract and Their Effect on Salivary Biomarkers and on Oral Health Condition in (19_24) Years Old
lozenges containing propolis - Plaque Induced Gingivitis, Mouth Diseases
Phase 1CompletedAl-Mustansiriyah University1002025-03-232025-09-24
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a - Amyloid Plaque, Beta-Amyloid
Phase 1 / Phase 2RecruitingAC Immune SA3042022-06-212026-07-10
Convalescent Plasma Therapy in Patients With COVID-19
Convalescent plasma - Convalescence, Corona Virus Infection
Phase 1CompletedBiofarma102020-05-012020-06-30
Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque
Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush - Gingivitis, Plaque
Phase 1CompletedJohnson & Johnson Consumer Inc. (J&JCI)1572019-10-082023-09-28
Blood Brain Barrier Opening in Alzheimer' Disease
SONOCLOUD® - Alzheimer Disease
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris102017-06-262022-04-12
Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis
scaling and root planing (srp) - Periodontitis, Menopause
Phase 1 / Phase 2CompletedPanineeya Mahavidyalaya Institute of Dental Sciences & Research Centre602015-01-012016-03-24
Evaluate the Effect of Elimune Capsules
Elimune Capsules - Plaque Psoriasis
Phase 1CompletedElorac, Inc.212014-09-012015-12-08
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
PF06263276, Vehicle, 2%Tofacitinib Ointment - Psoriasis Vulgaris
Phase 1CompletedPfizer152014-09-012016-06-09
A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
Bexarotene, Placebo - Alzheimer's Disease
Phase 1CompletedReXceptor, Inc.122014-08-012015-08-13
Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W - Plaque, Gingivitis
Phase 1 / Phase 2CompletedU.S. Army Medical Research and Development Command1352014-02-252020-02-13
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration - Atrophy, Geographic
Phase 1CompletedGlaxoSmithKline362014-01-222017-05-15
Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study
DD-25 - Psoriasis Vulgaris
Phase 1 / Phase 2UnknownFortuderm Ltd.302012-10-012012-10-08
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
[18Fluor]AZD4694 - Maximum Diagnostic Mass of [18Fluor]AZD4694
Phase 1CompletedAstraZeneca162011-08-012012-12-10
Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)
SNUBH-NM-333(18F) - Alzheimer Disease
Phase 1 / Phase 2TerminatedSeoul National University Hospital302010-12-012014-05-29

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Alzheimer Disease (13)  ·  Gingivitis (4)  ·  Psoriasis (3)  ·  Dementia (2)  ·  Arteriosclerosis (1)  ·  Brain Diseases (1)  ·  COVID-19 (1)  ·  Central Nervous System Diseases (1)  ·  Convalescence (1)  ·  Coronary Artery Disease (1)  ·  Coronavirus Infections (1)  ·  Down Syndrome (1)  ·  Frontotemporal Dementia (1)  ·  Geographic Atrophy (1)

Broader conditions

Pathological Conditions, Anatomical (27)  ·  Pathological Conditions, Signs and Symptoms (27)  ·  Mental Disorders (13)  ·  Nervous System Diseases (13)  ·  Neurocognitive Disorders (13)  ·  Tauopathies (13)  ·  Brain Diseases (12)  ·  Central Nervous System Diseases (12)  ·  Neurodegenerative Diseases (12)  ·  Dementia (11)  ·  Infections (5)  ·  Stomatognathic Diseases (5)  ·  Gingival Diseases (4)  ·  Mouth Diseases (4)  ·  Periodontal Diseases (4)

Interventions

4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (4)  ·  florbetapir (3)  ·  AZD2995 (1)  ·  Bexarotene (1)  ·  Fluorides (1)  ·  Organization and Administration (1)  ·  PF-06263276 (1)  ·  Propolis (1)  ·  Root Planing (1)  ·  Silicon Dioxide (1)  ·  Tooth Exfoliation (1)  ·  Urocortins (1)  ·  calcipotriene (1)  ·  tofacitinib (1)

Sponsors

Eli Lilly and Company (3)  ·  AstraZeneca (2)  ·  GlaxoSmithKline (2)  ·  Pfizer (2)  ·  AC Immune SA (1)  ·  Acta Pharmaceuticals (1)  ·  Al-Mustansiriyah University (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Biofarma (1)  ·  Cenna Biosciences Inc. (1)  ·  Chang Gung Memorial Hospital (1)  ·  Elorac, Inc. (1)  ·  Fortuderm Ltd. (1)  ·  GAAD Medical Research Institute Inc. (1)  ·  Johnson & Johnson Consumer Inc. (J&JCI) (1)

Countries

United States (12)  ·  China (3)  ·  Japan (3)  ·  Sweden (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Indonesia (1)  ·  Iraq (1)  ·  Israel (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Bjorn Paulsson (1)  ·  Craig T Curtis, MD (1)  ·  Domenick T Zero, DDS, MS (1)  ·  Doug Galasko, MD (1)  ·  Elisabeth Eden, MD (1)  ·  Emma Gyllenpalm (1)  ·  Hagit Matz, M.D. (1)  ·  Jeffery Milleman, DDS (1)  ·  Ken Nedd, M.D. (1)  ·  Kwasi Donyina, Ph.D. (1)

Results publications

PMID 24970906, PMID 29067298, PMID 33773598, PMID 34104878, PMID 3425152, PMID 34815790, PMID 35260178, PMID 3793432, PMID 38762482, PMID 39466933

NIH funding

2014 (1), 2016 (1)